Vertex Pharmaceuticals Q2 Revenue Tops Estimates, Raises Full-Year Guidance

Vertex Pharmaceuticals reported second-quarter revenue of $3.33 billion, surpassing the analyst consensus estimate of $3.23 billion. Adjusted earnings per share came in at $4.73, matching expectations.

GAAP EPS stood at $4.31, while adjusted net income was $1.21 billion, slightly below the forecasted $1.23 billion. The company also updated its full-year revenue guidance to a range of $13.1 billion to $13.2 billion, above the $13.07 billion Wall Street had projected.